Richard A. Larson to Leukemia, Myeloid, Chronic-Phase
This is a "connection" page, showing publications Richard A. Larson has written about Leukemia, Myeloid, Chronic-Phase.
Connection Strength
2.729
-
Is there a best TKI for chronic phase CML? Hematology Am Soc Hematol Educ Program. 2015; 2015:250-6.
Score: 0.495
-
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2012 May; 68(5):723-33.
Score: 0.402
-
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008 Apr 15; 111(8):4022-8.
Score: 0.307
-
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis. Haematologica. 2023 06 01; 108(6):1567-1578.
Score: 0.222
-
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016 05; 30(5):1044-54.
Score: 0.134
-
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica. 2014 Jul; 99(7):1204-11.
Score: 0.117
-
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol. 2014 Jan; 164(2):223-32.
Score: 0.114
-
Current practices in the management of chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):48-54.
Score: 0.106
-
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012 Nov 08; 120(19):3898-905.
Score: 0.105
-
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013 Jan; 27(1):107-12.
Score: 0.104
-
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011 Jan 27; 117(4):1141-5.
Score: 0.093
-
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun 17; 362(24):2251-9.
Score: 0.090
-
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. 2010 Jul; 24(7):1299-301.
Score: 0.090
-
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 2009 Feb 01; 115(3):551-60.
Score: 0.082
-
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804. Cancer Chemother Pharmacol. 2009 Apr; 63(5):859-64.
Score: 0.079
-
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008 Jun; 22(6):1200-6.
Score: 0.078
-
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol. 2003 Jun 01; 21(11):2138-46.
Score: 0.055
-
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003 Mar 13; 348(11):994-1004.
Score: 0.055